AMGN 억만장자 켄 피셔의 최고 15가지 움직임

What happened: Amgen Inc. (NASDAQ:AMGN) has seen a surge in bullish sentiment from analysts and investors. Morgan Stanley raised its price target to $326, while Wells Fargo increased theirs to $390. These moves follow Amgen's announcement that its drug Repatha® showed significant cardiovascular benefits. Billionaire Ken Fisher also doubled his bullish position in Amgen.

Market impact: This positive sentiment has driven up Amgen's stock price, benefiting shareholders. The biotech sector, particularly companies with strong pipelines like Amgen, may see increased investor interest. Meanwhile, BTG Pactual's cautious stance on Tyson Foods (NYSE:TSN) highlights a contrasting view in another high-dividend stock.

What to watch next: Amgen's Q1 earnings, scheduled for April 27, will provide insights into the company's financial health and pipeline progress. Additionally, the FDA's decision on Amgen's Aimovig® label expansion, expected in Q2, could further impact the stock. Lastly, investors will monitor Ken Fisher's continued activity in Amgen's stock.